key: cord-0778983-j20cj7qa
authors: Doan, Thuy; Hinterwirth, Armin; Arzika, Ahmed M; Worden, Lee; Chen, Cindi; Zhong, Lina; Oldenburg, Catherine E; Keenan, Jeremy D; Lietman, Thomas M
title: Reduction of coronavirus burden with mass azithromycin distribution
date: 2020-05-19
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa606
sha: 392768cf6d2f88f66d8f60c164329dd1ba0b2c9e
doc_id: 778983
cord_uid: j20cj7qa

We evaluated the potential antiviral effects of azithromycin on the nasopharyngeal virome of Nigerien children who had received multiple rounds of mass drug administration. We found that the respiratory burden of non-SARS coronaviruses was decreased with azithromycin distributions.

Mass oral azithromycin distribution decreased childhood mortality in Sub-Saharan Africa. [1] Verbal autopsy revealed fewer deaths in communities treated with azithromycin from a number of infectious diagnoses, including dysentery and pneumonia. [2] Consistent with azithromycin's antibacterial properties, the gut pathogen load was reduced after the 4 th biannual azithromycin distribution. [3] Because azithromycin may also have antiviral properties [4, 5] , we performed an exploratory analysis on the effects of azithromycin on respiratory viral pathogens.

Trial Oversight: We obtained ethical approval for the study from the University of California, San Francisco (UCSF) Committee for Human Research and the Ethical Committee of the Niger Ministry of Health (IRB # 10-01036). The study was undertaken in accordance with the Declaration of Helsinki.

We obtained verbal informed consent from guardians of children prior to treatment and swab collection. No incentives were offered.

Eligibility: As part of MORDOR (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) I and II (NCT02047981) [3] , 30 communities in the Dosso region of Niger were randomly selected for enrollment in a smaller sister trial to assess for infectious disease outcomes. The randomization unit was at the community level. All children aged 1 to 59 months and weighing at least 3800 grams were eligible for treatment. One community declined further participation after 24 months ( Figure S1 ). Therefore, there were 29 participating communities at the 36-month time point.

A c c e p t e d M a n u s c r i p t 4 Intervention: Children aged 1-59 months were randomized to receive one oral dose of placebo or azithromycin (height-based dosing to a target dose of 20 mg/kg) every 6 months for 3 years. All field and laboratory personnel were masked to the assignments.

Approximately 40 children from each of the 30 villages were randomly selected for sample collection at each time point ( Figure S1 ). The children selected for sample collection at baseline may not be the same children selected at subsequent time points, and some children aged out of eligibility during the trial. Nasopharyngeal swabs were obtained at baseline (prior to treatment), 24 months (6 months after the 4 th treatment), and 36 months (6 months after the 6 th treatment). Samples were immediately placed in DNA/RNA Shield (Zymo Research) to deactivate pathogens and preserve nucleic acid integrity. The samples were placed on ice packs in the field, stored at -20°C in Niger, and shipped to UCSF for long-term storage at -80°C until sample processing. Sequencing data were analyzed using a rapid, in-house computational pipeline to classify sequencings reads by comparison to the entire NCBI nucleotide (nt) reference database. [3, 6] A c c e p t e d M a n u s c r i p t 5 DESeq2 was used to perform differential abundance analysis on the DNA and RNA viruses identified across all samples [7] . Topconfects algorithm was used to determine the confident effect sizes. [8] 

We analyzed 890 nasopharyngeal samples from preschool children in the Dossa region of Niger that were collected from 2015 to 2018. Characteristics of children whose samples were sequenced and analyzed are shown in Table S1 . At baseline, prior to treatment, Alphacoronavirus was more abundant in the nasopharynx of children randomized to the azithromycin arm ( Figure S2 ). There was no difference in either abundance or prevalence of other virus genera between arms. At 24 months,

Alphacoronavirus and a 14-fold reduction in Betacoronavirus compared to children from villages treated with placebo ( Figure 1A) . At 36 months, Betacoronavirus was again observed to be differentially abundant between treatment groups, but with a modest 1.6-fold relative reduction in the azithromycin arm. Other genera found to be differential between treatments were Enterovirus, Respirovirus, and Lymphocryptovirus. At the species level, Coronavirus-HKU1 and Coronavirus-NL63 abundances were significantly reduced in the azithromycin group at 24 months, and again at 36 months (Coronavirus-HKU1) ( Figure 1A) . We were unable to detect a significant change in the proportion of children who harbored any evidence of coronavirus with azithromycin compared to placebo at either the 24-or 36-month time points (Figure 1B) . These results suggest that mass azithromycin distribution may decrease viral load, but not the prevalence of colonization in a community. Coronavirus-HKU1 and Coronavirus-NL63 are human pathogens that have been reported worldwide.[9, 10] Disease manifestations include respiratory tract infections, meningitis, and gastroenteritis, and are generally self-limiting although deaths have been documented in immunocompromised patients. [11] Whether mass azithromycin distribution provides herd effects or directly protects a treated child is unclear, as this study was not designed to determine the effects of mass azithromycin distribution on viral infections causing mortality. It is also unclear if clinical severity is dependent on viral load.

Macrolides have long been hypothesized to have therapeutic effects on viral infections, either via its anti-inflammatory effects or its off-target effects on viral replication. Recently, azithromycin is shown to have activity against SARS-CoV-2 in vitro. [12] Preliminary evidence has also suggested that azithromycin may reduce viral load in patients with SARS-CoV-2 infection, although these studies were non-randomized and suffered from small sample sizes. [13] Therefore, it remains to be determined if the observations seen in this study are translatable to SARS-CoV-2 or if treatment with azithromycin provides any clinical protection against SARS-CoV-2.

Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

Cause-specific mortality of children younger than 5 years in communities receiving biannual mass azithromycin treatment in Niger: verbal autopsy results from a cluster-randomised controlled trial

Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution

Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells

Zika virus cell tropism in the developing human brain and inhibition by azithromycin

Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Topconfects: a package for confident effect sizes in differential expression analysis provides a more biologically useful ranked gene list

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Human coronavirus in young children hospitalized for acute respiratory illness and asymptomatic controls

Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19

Macrolide treatment for COVID-19: Will this be the way forward?

M a n u s c r i p t 7 This cluster-randomized controlled trial is limited by the absence of data on respiratory symptoms and the non-prespecified nature of the analyses. Moreover, the generalizability of the results outside of pre-school Nigerien children is unclear.In summary, children in Niger treated with biannual mass azithromycin distributions experienced an associated decrease in the respiratory viral burden of non-SARS coronaviruses. A c c e p t e d M a n u s c r i p t 12 Figure 1